14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
YMAT vs ABVX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Abivax SA (ABVX) is the stronger overall head-to-head candidate over J-Star Holding Co., Ltd. (YMAT) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). YMAT carries a Unified Composite Score of 57.8/100 (HOLD) at $0.89 (N/M Forward P/E, -372.2% operating margin), whereas ABVX carries 55.3/100 (HOLD) at $83.61 (N/M Forward P/E, -6270.4% operating margin).
Composite vs. Pillar Nuance: While YMAT currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. ABVX 55.3/100 HOLD), ABVX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-6270.4% vs. -372.2% operating margin) and revenue trajectory (-6.8% vs. -36.1% YoY).
Technical & Structure Timing Caution: YMAT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.8); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on YMAT vs ABVX. Trailing 12-month operating profitability (YMAT -372.2% vs ABVX -6270.4%) and valuation multiples (YMAT N/M vs ABVX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $7.7B market capitalization and -6270.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ YMAT vs ABVX Key Questions & Quantitative Answers
As of Nov 16, 2026, Abivax SA (ABVX) is the stronger overall head-to-head candidate over J-Star Holding Co., Ltd. (YMAT) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). YMAT carries a Unified Composite Score of 57.8/100 (HOLD) at $0.89 (N/M Forward P/E, -372.2% operating margin), whereas ABVX carries 55.3/100 (HOLD) at $83.61 (N/M Forward P/E, -6270.4% operating margin). Composite vs. Pillar Nuance: While YMAT currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. ABVX 55.3/100 HOLD), ABVX captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-6270.4% vs. -372.2% operating margin) and revenue trajectory (-6.8% vs. -36.1% YoY). Technical & Structure Timing Caution: YMAT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.8); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABVX leads the Growth & Scale pillar: YMAT posts -36.1% YoY revenue growth and -56.4% YoY earnings growth on $6.1M TTM revenue (57.0% gross margin, -372.2% operating margin), compared with ABVX at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $4.7M TTM revenue (100.0% gross margin, -6270.4% operating margin). On trailing 12-month operating scale, YMAT generates $6.1M in USD-normalized revenue versus $4.7M for ABVX. In operating R&D and SG&A reinvestment, YMAT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVX.
YMAT screens cheaper on headline valuation multiples. YMAT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin), whereas ABVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against YMAT (-275.9% ROE) versus ABVX (-252.3% ROE) capital efficiency.
In options market volatility and institutional positioning, YMAT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (5.73β · 218% Vol realized risk). By comparison, ABVX carries 76.9% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 49% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.